Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

HAEAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ717.00− 1.19%S&P 500 · SPY769.88− 0.31%Dow Jones · DIA523.20− 0.28%Russell 2000 · IWM284.95+ 1.30%

Haemonetics Corporation (HAE) Gains on Strong Plasma Growth and Higher Guidance, Ariel Appreciation Fund Says
Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” Q3 2026 investor letter. A copy of the letter can be downloaded here. Copy main article 1st para. The Fund faced a challenging third quarter of 2026 as rising interest rates, higher energy prices, persistent inflation, and geopolitical uncertainty weighed on mid-cap equities, despite […]
Yahoo12:5022 Hours AgoHAE+1.6%

11:00Oct 271 Story

All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy
Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Yahoo11:00HAE+1.6%

23:00Oct 221 Story

Haemonetics Consensus Price Target Raised 24.88% to $145.63
Fintel23:53HAE+1.6%

13:00Oct 211 Story

Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?
Haemonetics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 96.3%, reaching $118.21 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Yahoo13:02HAE+1.6%

12:00-17:00Oct 192 Stories

Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of the PerQseal® Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics' portfolio of clinically-differentiated large-bore closure devices for structural heart and endovascular procedures in the U.S., following the company's acquisition
Yahoo16:15HAE+1.6%
Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval
Benzinga12:16

07:00Oct 161 Story

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
Yahoo07:14HAE+1.6%

08:00Oct 151 Story

Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.
Yahoo08:28HAE+1.6%

HAE▲+1.6%